A Prodrug of Epigallocatechin-3-gallate Alleviates High Glucose-Induced Pro-Angiogenic Factor Production by Inhibiting the ROS/TXNIP/NLRP3 Inflammasome Axis in Retinal Müller Cells.

Jingxia Du,Ying Wang,Yuanyuan Tu,Yang Guo,Xiaodong Sun,Xun Xu,Xiaojuan Liu,Li Wang,Xiao Qin,Manhui Zhu,E. Song

DOI: https://doi.org/10.1016/j.exer.2020.108065

IF: 3.77

2020-01-01

Experimental Eye Research

Abstract:Diabetic retinopathy (DR) is a neurovascular complication of diabetes mellitus that leads to blindness in the working-age population. Retinal Müller cells proliferate and produce pro-angiogenic factors, including vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), via the reactive oxygen species (ROS)/thioredoxin interacting protein (TXNIP)/NACHT, LRR and PYD domain-containing protein 3 (NLRP3) inflammasome axis to promote proliferative DR. Epigallocatechin-3-gallate (EGCG) plays anti-oxidant, anti-inflammatory, anti-proliferative and anti-angiogenic roles in Müller cells. A prodrug of EGCG (pro-EGCG) enhances the bioavailability of EGCG. In an in vitro model of high glucose-stimulated Müller cells, pro-EGCG inhibited proliferation and pro-angiogenic factor production by down-regulating the activity of the ROS/TXNIP/NLRP3 inflammasome axis. In a mouse DR model, pro-EGCG reduced ROS accumulation, NLRP3 inflammasome activation, Müller cell proliferation, and production of the pro-angiogenic factors VEGF and HGF. In summary, pro-EGCG mitigated hyperglycaemia-challenged Müller cell proliferation and pro-angiogenic factor production by inhibiting ROS/TXNIP/NLRP3 inflammasome signalling, implying a potential therapeutic strategy for DR.